Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Mid Cap Fund median (33 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Apr 2006 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty Midcap 150 history starts 14 Jan 2019, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | UTI - Mid Cap Fund |
|---|---|
| 03 Apr 2006 | ₹100.00 |
| 14 Dec 2007 | ₹110.56 |
| 26 Aug 2009 | ₹67.87 |
| 08 May 2011 | ₹85.11 |
| 17 Jan 2013 | ₹98.99 |
| 30 Sep 2014 | ₹188.46 |
| 11 Jun 2016 | ₹187.17 |
| 21 Feb 2018 | ₹223.83 |
| 04 Nov 2019 | ₹200.58 |
| 16 Jul 2021 | ₹329.12 |
| 28 Mar 2023 | ₹332.73 |
| 08 Dec 2024 | ₹598.46 |
| 20 Aug 2026 | ₹615.51 |
| Metric | UTI · Regular · IDCW NAV ₹152.09 Very High risk ★★★☆☆ | Category median Mid Cap Fund · 33 funds |
|---|---|---|
| +5.59% | +4.36% | |
| +13.78% | +14.16% | |
| +13.38% | +13.38% | |
| +11.54% | +7.79% | |
| +9.33% | +9.71% | |
| +13.01% | — | |
| +12.96% | +11.96% | |
| +12.80% | +10.86% | |
| +12.38% | +9.43% | |
| Risk | ||
| 15.29% | 17.59% | |
| 0.48 | 0.44 | |
| 0.65 | 0.61 | |
| -68.43% | -47.34% | |
| Nifty Midcap 150 | — | |
| -3.15% | -3.13% | |
| 0.94 | 0.97 | |
| 89.1% | 91.4% | |
| 101.4% | 102.1% | |
| 1.96% | 2.04% | |
| ₹11,737Cr | ₹9,315Cr | |
| 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 25% | 41% | |
| Vishal Chopda | — | |
| 03 Apr 2006 | — | |
| 91 | — | |
| 22.2% | — | |
| 0.9% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.